Mission Protocol 01

The RetraLabs
Foundation.

"At RetraLabs, we source our peptides directly from trusted manufacturers from our partner china who offer genuine quality at transparent, fair pricing. Our goal is simple: to provide legit, research-grade peptides at reasonable prices without scams or shortcuts."

We are new to the Indian market, and we genuinely appreciate your support as we build something reliable and long-term here.

Before starting RetraLabs, we personally faced difficulties finding authentic peptide sources in India. Through extensive research, we realized that there is currently no verified, genuine source of Retatrutide or other UGL peptides available domestically. That gap is exactly why RetraLabs exists.

We operate with complete transparency and integrity. All products are handled carefully, and we take responsibility for sourcing, customs clearance, and quality control. Our focus is on purity, consistency, and honest communication.

The Trust Covenant

Trust is earned. If you feel a product is not performing as expected, or if you have a valid lab report showing purity below acceptable standards, we are open to discussion and will offer a refund or appropriate compensation.

Important: Retatrutide is currently not FDA-approved and is intended for laboratory research only.

Future of Cellular Longevity

Engineered for
Scientific Elite.

RetraLabs delivers pharmaceutical-grade peptides synthesized for the most rigorous research standards. Transparent, pure, and unapologetically premium.

Curated Synthesis

The Collection.

Engineered for absolute purity. Our compounds represent the pinnacle of current peptide synthesis technology.

Flagship Protocol 99.8% Certified Purity

Retatrutide

Triple Agonist Construct

Starting at ₹11,000

The most advanced metabolic research compound currently synthesized. Engineered for unprecedented receptor affinity.

Analyze Dosages
Q1 2026

Tirzepatide

Dual Agonist Protocol

Queue Status Opening Soon

Currently undergoing final molecular stability verification. Advanced weight management pathways.

Semaglutide

GLP-1 Receptor Agonist

Scientific Briefing

Clinical Analysis:
Retatrutide.

Retatrutide (LY3437943) represents a breakthrough in metabolic research as a **Triple Agonist Construct**, targeting GIP, GLP-1, and Glucagon receptors simultaneously.

24.2%
Mean Weight Loss

Phase 2 trials @ 48 weeks (highest dose)

Triple
Receptor Affinity

GIP, GLP-1, and GCGR multi-pathway activation

Retatrutide research suggests enhanced energy expenditure through glucagon receptor activation, differentiating it from dual-agonist protocols.

Crowdsourced Research

For real-world laboratory discussions, protocol optimizations, and peer-reviewed dosing analysis, we strongly recommend visiting the Retatrutide research community on Reddit.

Target Community
r/retatrutide
Analyze on Reddit
Current Inventory

Research Catalogues.

Select verified concentrations for your specific laboratory research requirements.

Retatrutide Protocol

Verified Batch
5mg
In Stock

Retatrutide

5mg * 10 VIALS PER KIT

₹11,000
10mg
Limited

Retatrutide

10MG * 10 VIALS PER KIT

₹18,000
Additional Protocols
Q2 2026 Batch

Synthesis Pipeline

Q1 2026

GHK-Cu

In Stability Testing

Pending

HGH 191AA

Quality Control

Pipeline

IGF-1 LR3

Synthesis Step 04

Q2 2026

5-Amino-1MQ

Awaiting Raw Batch

Strict Research Protocol.

RetraLabs maintains the highest ethical standards in biotech distribution. All compounds listed are strictly for In-Vitro Laboratory Research.

Non-Human Use
Vetted Facilities Only